Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction

Jiang, Xuejun; Wang, Tao; Li, Xiaoyan; Wu, Dequn; Zheng, Zhao-Bin; Zhang, Jinfeng; Chen, Jinling; Peng, Bin; Jiang, Hong; Huang, Congxin; Zhang, Xian‐Zheng

doi:10.1002/jbm.a.32118

Cited by 87 publications

(59 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No increase in neovascularization was observed [32]. In 1-week-old infarcts in a rabbit model, significant improvements in thickness, infarct size, LVEDD, LVESD, and EF were observed with no increase in microvessel density [24].…”

Section: Synthetic Hydrogelsmentioning

confidence: 86%

“…Another synthetic material consisting of α-cyclodextrin (α-CD) and poly(ethylene glycol) (MPEG-PCL-MPEG) triblock copolymer that has the ability to gel in situ has also demonstrated therapeutic benefits when injected to target LV remodeling [24,32]. Degradation can be controlled by the PCL block, and hydrogels were formed upon mixing the linear MPEG-PCL-MPEG polymer with α-CD.…”

Section: Synthetic Hydrogelsmentioning

confidence: 99%

“…If anything, these results reveal the complexity in the material interaction with the myocardial tissue, including both the biological (e.g., material remodeling and inflammatory response) and mechanical (e.g., stress reduction) responses. Variable results from these studies indicate that material thickness [21,26,29,34], infarct size [22] [34], and/or increased angiogenesis [19,24,64] do not necessarily correlate directly with improved heart function. However, discrepancies in results could be due to inconsistencies in methodology (Table 1; e.g., animal models, infarct, amount of material injected, and timing of injection), and material properties and the importance of these parameters should be considered when investigating LV remodeling.…”

Section: Limitations Of Experimental Assessment Of Bulking Agentsmentioning

confidence: 99%

“…However, these approaches are limited by the invasive procedure in which they are applied, and clinical adoption has not occurred. In order to circumvent the invasive surgical placement of restraining devices early post-MI, our group and others have begun to explore the use of injectable materials, and specifically hydrogels, to limit infarct expansion and normalize the regional stress distribution [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Injectable Acellular Hydrogels for Cardiac Repair

Tous

Purcell

Ifkovits

et al. 2011

J. of Cardiovasc. Trans. Res.

150

136

View full text Add to dashboard Cite

Injectable hydrogels are being developed as potential translatable materials to influence the cascade of events that occur after myocardial infarction. These hydrogels, consisting of both synthetic and natural materials, form through numerous chemical crosslinking and assembly mechanisms and can be used as bulking agents or for the delivery of biological molecules. Specifically, a range of materials are being applied that alter the resulting mechanical and biological signals after infarction and have shown success in reducing stresses in the myocardium and limiting the resulting adverse left ventricular (LV) remodeling. Additionally, the delivery of molecules from injectable hydrogels can influence cellular processes such as apoptosis and angiogenesis in cardiac tissue or can be used to recruit stem cells for repair. There is still considerable work to be performed to elucidate the mechanisms of these injectable hydrogels and to optimize their various properties (e.g., mechanics and degradation profiles). Furthermore, although the experimental findings completed to date in small animals are promising, future work needs to focus on the use of large animal models in clinically relevant scenarios. Interest in this therapeutic approach is high due to the potential for developing percutaneous therapies to limit LV remodeling and to prevent the onset of congestive heart failure that occurs with loss of global LV function. This review focuses on recent efforts to develop these injectable and acellular hydrogels to aid in cardiac repair.

show abstract

Section: Synthetic Hydrogelsmentioning

confidence: 86%

Section: Synthetic Hydrogelsmentioning

confidence: 99%

Section: Limitations Of Experimental Assessment Of Bulking Agentsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Injectable Acellular Hydrogels for Cardiac Repair

Tous

Purcell

Ifkovits

et al. 2011

J. of Cardiovasc. Trans. Res.

150

136

View full text Add to dashboard Cite

show abstract

“…Nowadays synthetic materials have achieved high degrees of biodegradation and biocompatibility, like their natural counterparts. In fact, cardiac administration of synthetic hydrogels has proved to be effective in terms of promoting contractile phenotype smooth muscle tissue formation [46,47], preventing LV remodeling and scar expansion and improving cardiac function [48][49][50][51]. Interestingly, the timing of administration seems to be important because hydrogels assumed markedly different morphologies that determined heart remodeling.…”

Section: Hydrogelsmentioning

confidence: 99%

Heart regeneration after myocardial infarction using synthetic biomaterials

Pascual-Gil

Garbayo

Díaz-Herráez

et al. 2015

Journal of Controlled Release

122

View full text Add to dashboard Cite

Abstract:Myocardial infarction causes almost 7.3 million deaths each year worldwide. However, current treatments are more palliative than curative. Presently, cell and protein therapies are considered the most promising alternative treatments. Clinical trials performed until now have demonstrated that these therapies are limited by protein short half-life and by low transplanted cell survival rate, prompting the development of novel cell and protein delivery systems able to overcome such limitations. In this review we discuss the advances made in the last 10 years in the emerging field of cardiac repair using biomaterial-based delivery systems with focus on the progress made on preclinical in vivo studies. Then, we focus in cardiac tissue engineering approaches, and how the incorporation of both cells and proteins together into biomaterials has opened new horizons in the myocardial infarction treatment. Finally, the ongoing challenges and the perspectives for future work in cardiac tissue engineering will also be discussed.

show abstract